A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00871936
Recruitment Status : Completed
First Posted : March 30, 2009
Last Update Posted : February 19, 2015
Information provided by (Responsible Party):
Kadmon Corporation, LLC

Brief Summary:
The purpose of this study is to determine whether SLx-4090 in combination with metformin therapy will reduce HbA1c in patients with Type 2 Diabetes more effectively than metformin therapy alone.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Drug: SLx-4090 Other: Placebo Drug: Metformin Phase 2

Detailed Description:
  1. HbA1c after 12 weeks
  2. FPG after 12 weeks
  3. Safety and tolerability
  4. Plasma levels of SLx-4090

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 82 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of SLx-4090 in Combination With Metformin in Subjects With Type 2 Diabetes
Study Start Date : April 2009
Primary Completion Date : October 2009
Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
SLx-4090 in combination with Metformin
Drug: SLx-4090
Drug: Metformin
Other: Placebo
matching tablets
Drug: Metformin

Primary Outcome Measures :
  1. Reduction in HbA1c [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Adverse Events [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HbA1c 7-11%
  • On a stable dose of metformin for at least 6 weeks

Exclusion Criteria:

  • Type 1 Diabetes
  • Antidiabetic medication other than or in addition to metformin
  • FPG > 270 mg/dL

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00871936

United States, California
Anaheim, California, United States, 92801
Burbank, California, United States, 91505
Los Angeles, California, United States, 90036
Los Angeles, California, United States, 90057
United States, Florida
West Palm Beach, Florida, United States, 33401
United States, Illinois
Addison, Illinois, United States, 60101
United States, Maine
Auburn, Maine, United States, 04210
United States, North Carolina
Charlotte, North Carolina, United States, 28211
Hickory, North Carolina, United States, 28602
Winston-Salem, North Carolina, United States, 27103
United States, South Carolina
Greenville, South Carolina, United States, 29615
United States, Texas
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Kadmon Corporation, LLC

Responsible Party: Kadmon Corporation, LLC Identifier: NCT00871936     History of Changes
Other Study ID Numbers: SLx-4090-09-07
First Posted: March 30, 2009    Key Record Dates
Last Update Posted: February 19, 2015
Last Verified: February 2015

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs